Primidone, which has been approved by FDA, can decrease TNFα-mediated inflammation in vivo and RIPK1-triggered necroptosis in vitro, and is thereby good for COVID-19 cases.83 In addition, Necrostatin-1 (Nec-1) accounts for the necroptosis inhibitor targeting RIPK1. The gene discussed is RIPK1; the disease is COVID-19.